RU2154671C1 - Днк-фрагмент, кодирующий 3-фосфоглицератдегидрогеназу (фгд), фгд, способ получения серина - Google Patents
Днк-фрагмент, кодирующий 3-фосфоглицератдегидрогеназу (фгд), фгд, способ получения серина Download PDFInfo
- Publication number
- RU2154671C1 RU2154671C1 RU94030817/13A RU94030817A RU2154671C1 RU 2154671 C1 RU2154671 C1 RU 2154671C1 RU 94030817/13 A RU94030817/13 A RU 94030817/13A RU 94030817 A RU94030817 A RU 94030817A RU 2154671 C1 RU2154671 C1 RU 2154671C1
- Authority
- RU
- Russia
- Prior art keywords
- serine
- fgd
- phosphoglycerate dehydrogenase
- dna fragment
- dna
- Prior art date
Links
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 239000012634 fragment Substances 0.000 title claims abstract description 21
- 108010038555 Phosphoglycerate dehydrogenase Proteins 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title abstract description 15
- 230000035945 sensitivity Effects 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims abstract description 9
- 230000005764 inhibitory process Effects 0.000 claims abstract description 9
- 239000013604 expression vector Substances 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract description 56
- 230000000694 effects Effects 0.000 abstract description 18
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 238000010353 genetic engineering Methods 0.000 abstract description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 4
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 1
- 229960001153 serine Drugs 0.000 description 51
- 108090000623 proteins and genes Proteins 0.000 description 30
- 230000015572 biosynthetic process Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 229960000723 ampicillin Drugs 0.000 description 10
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 10
- 230000003197 catalytic effect Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 230000010354 integration Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 6
- 210000000349 chromosome Anatomy 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 230000002759 chromosomal effect Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 229930027917 kanamycin Natural products 0.000 description 5
- 229960000318 kanamycin Drugs 0.000 description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 5
- 229930182823 kanamycin A Natural products 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 150000003212 purines Chemical class 0.000 description 4
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 235000013902 inosinic acid Nutrition 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000012261 overproduction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 150000003354 serine derivatives Chemical class 0.000 description 3
- 239000005460 tetrahydrofolate Substances 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108050009160 DNA polymerase 1 Proteins 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- -1 for example Chemical compound 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- LELJBJGDDGUFRP-REOHCLBHSA-N (2s)-2-amino-n,3-dihydroxypropanamide Chemical compound OC[C@H](N)C(=O)NO LELJBJGDDGUFRP-REOHCLBHSA-N 0.000 description 1
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 description 1
- LFLUCDOSQPJJBE-UHFFFAOYSA-N 3-phosphonooxypyruvic acid Chemical compound OC(=O)C(=O)COP(O)(O)=O LFLUCDOSQPJJBE-UHFFFAOYSA-N 0.000 description 1
- MJEQLGCFPLHMNV-UHFFFAOYSA-N 4-amino-1-(hydroxymethyl)pyrimidin-2-one Chemical compound NC=1C=CN(CO)C(=O)N=1 MJEQLGCFPLHMNV-UHFFFAOYSA-N 0.000 description 1
- PFJBDCNEHIXTLU-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@]1(CO)[C@H](O)[C@H](O)[C@@H](CO)O1 PFJBDCNEHIXTLU-VPCXQMTMSA-N 0.000 description 1
- QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-methylenetetrahydrofolic acid Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 101500006448 Mycobacterium bovis (strain ATCC BAA-935 / AF2122/97) Endonuclease PI-MboI Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108010030161 Serine-tRNA ligase Proteins 0.000 description 1
- 102100040516 Serine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000004034 genetic regulation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/06—Alanine; Leucine; Isoleucine; Serine; Homoserine
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Epoxy Resins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Tires In General (AREA)
- Ceramic Products (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP91121385 | 1991-12-12 | ||
| DE91121385,8 | 1991-12-12 | ||
| DE91121385.8 | 1991-12-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU94030817A RU94030817A (ru) | 1996-03-10 |
| RU2154671C1 true RU2154671C1 (ru) | 2000-08-20 |
Family
ID=8207424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU94030817/13A RU2154671C1 (ru) | 1991-12-12 | 1992-08-17 | Днк-фрагмент, кодирующий 3-фосфоглицератдегидрогеназу (фгд), фгд, способ получения серина |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5618716A (cg-RX-API-DMAC10.html) |
| EP (1) | EP0620853B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2584409B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR0132258B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN1065914C (cg-RX-API-DMAC10.html) |
| AU (1) | AU668359B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR9206902A (cg-RX-API-DMAC10.html) |
| CA (1) | CA2124214C (cg-RX-API-DMAC10.html) |
| CZ (1) | CZ285915B6 (cg-RX-API-DMAC10.html) |
| DE (1) | DE69208894T2 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2084373T3 (cg-RX-API-DMAC10.html) |
| FI (1) | FI113665B (cg-RX-API-DMAC10.html) |
| HU (1) | HU217795B (cg-RX-API-DMAC10.html) |
| RU (1) | RU2154671C1 (cg-RX-API-DMAC10.html) |
| SK (1) | SK279805B6 (cg-RX-API-DMAC10.html) |
| TW (1) | TW313589B (cg-RX-API-DMAC10.html) |
| UA (1) | UA39861C2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO1993012235A1 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA926405B (cg-RX-API-DMAC10.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2346038C2 (ru) * | 2002-07-19 | 2009-02-10 | Ваккер Хеми Аг | Способ ферментативного получения аминокислот и производных аминокислот из семейства фосфоглицератов |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4232468A1 (de) * | 1992-09-28 | 1994-03-31 | Consortium Elektrochem Ind | Mikroorganismen für die Produktion von Tryptophan und Verfahren zu ihrer Herstellung |
| JP3997631B2 (ja) | 1998-01-12 | 2007-10-24 | 味の素株式会社 | 発酵法によるｌ−セリンの製造法 |
| JP4066543B2 (ja) * | 1998-01-12 | 2008-03-26 | 味の素株式会社 | 発酵法によるｌ−セリンの製造法 |
| US6431870B1 (en) | 1999-11-30 | 2002-08-13 | Ora Metrix, Inc. | Method and apparatus for generating a desired three-dimensional digital model of an orthodontic structure |
| US6350120B1 (en) | 1999-11-30 | 2002-02-26 | Orametrix, Inc. | Method and apparatus for designing an orthodontic apparatus to provide tooth movement |
| US6250918B1 (en) | 1999-11-30 | 2001-06-26 | Orametrix, Inc. | Method and apparatus for simulating tooth movement for an orthodontic patient |
| US6471512B1 (en) | 1999-11-30 | 2002-10-29 | Ora Metrix, Inc. | Method and apparatus for determining and monitoring orthodontic treatment |
| US6540512B1 (en) | 1999-11-30 | 2003-04-01 | Orametrix, Inc. | Method and apparatus for treating an orthodontic patient |
| WO2001083791A2 (en) * | 2000-05-02 | 2001-11-08 | Agrinomics, Llc | Identification and characterization of a pagoda phenotype (pgd) in plants |
| DE10331291A1 (de) * | 2003-07-10 | 2005-02-17 | Consortium für elektrochemische Industrie GmbH | Varianten der 3-Phosphoglyceratdehydrogenase mit reduzierter Hemmung durch L-Serin und dafür codierende Gene |
| EP1871274B1 (en) | 2005-03-07 | 2019-05-08 | Align Technology, Inc. | Wrinkled dental aligner |
| US20060275731A1 (en) | 2005-04-29 | 2006-12-07 | Orthoclear Holdings, Inc. | Treatment of teeth by aligners |
| DE102005049527B4 (de) * | 2005-10-17 | 2013-05-08 | Forschungszentrum Jülich GmbH | Verfahren zur Herstellung von L-Serin, Gensequenz, Vektoren sowie Mikroorganismus |
| RU2006129690A (ru) | 2006-08-16 | 2008-02-27 | Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) (RU) | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТЫ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИЙ СЕМЕЙСТВА Enterobacteriaceae, В КОТОРОЙ ОСЛАБЛЕНА ЭКСПРЕССИЯ ГЕНА ydiN, ГЕНА ydiB ИЛИ ИХ КОМБИНАЦИИ |
| JP2010017082A (ja) * | 2006-10-10 | 2010-01-28 | Ajinomoto Co Inc | Ｌ−アミノ酸の製造法 |
| JP2010017081A (ja) * | 2006-10-10 | 2010-01-28 | Ajinomoto Co Inc | Ｌ−アミノ酸の製造法 |
| WO2009031565A1 (ja) | 2007-09-04 | 2009-03-12 | Ajinomoto Co., Inc. | アミノ酸生産微生物及びアミノ酸の製造法 |
| JP5332237B2 (ja) * | 2008-03-06 | 2013-11-06 | 味の素株式会社 | Ｌ−システイン生産菌及びｌ−システインの製造法 |
| US8383372B2 (en) * | 2008-03-06 | 2013-02-26 | Ajinomoto Co., Inc. | L-cysteine producing bacterium and a method for producing L-cysteine |
| KR101827230B1 (ko) | 2008-12-31 | 2018-02-07 | 메타볼릭 익스플로러 | 디올의 제조 방법 |
| ES2646165T3 (es) | 2009-11-30 | 2017-12-12 | Ajinomoto Co., Inc. | Bacteria que produce L-cisteína y procedimiento para la producción de L-cisteína |
| US8911978B2 (en) | 2010-07-02 | 2014-12-16 | Metabolic Explorer | Method for the preparation of hydroxy acids |
| DE102011075656A1 (de) | 2011-05-11 | 2012-03-29 | Wacker Chemie Ag | Verfahren zur fermentativen Produktion von L-Cystin |
| DE102011078481A1 (de) | 2011-06-30 | 2013-01-03 | Wacker Chemie Ag | Verfahren zur fermentativen Produktion von natürlichem L-Cystein |
| DE102012208359A1 (de) | 2012-05-18 | 2013-11-21 | Wacker Chemie Ag | Verfahren zur fermentativen Produktion von L-Cystein und Derivaten dieser Aminosäure |
| DE102012216527A1 (de) | 2012-09-17 | 2014-03-20 | Wacker Chemie Ag | Verfahren zur fermentativen Produktion von L-Cystein und Derivaten dieser Aminosäure |
| WO2014049382A2 (en) | 2012-09-26 | 2014-04-03 | Metabolic Explorer | Ethylenediamine fermentative production by a recombinant microorganism |
| DE102013209274A1 (de) | 2013-05-17 | 2014-11-20 | Wacker Chemie Ag | Mikroorganismus und Verfahren zur fermentativen Überproduktion von Gamma-Glutamylcystein und Derivaten dieses Dipeptids |
| EP3908663A1 (en) | 2019-02-20 | 2021-11-17 | Braskem S.A. | Microorganisms and methods for the production of oxygenated compounds from hexoses |
| WO2020168408A1 (en) | 2019-02-20 | 2020-08-27 | Braskem S.A. | Degradation pathway for pentose and hexose sugars |
| CN116018400A (zh) | 2020-06-26 | 2023-04-25 | 瓦克化学股份公司 | 改进的产生半胱氨酸的菌株 |
| EP4463466A1 (de) | 2022-03-01 | 2024-11-20 | Wacker Chemie AG | Verbesserte cystein produzierende stämme |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0190921A3 (en) * | 1985-02-04 | 1988-01-13 | Engenics, Inc. | Method for the overproduction of amino acids |
| US4743546A (en) * | 1985-02-13 | 1988-05-10 | Biotechnica International, Inc. | Controlled gene excision |
| US4753883A (en) * | 1986-05-07 | 1988-06-28 | Biotechnica International, Inc. | Enzyme deregulation |
| US4753833A (en) * | 1986-09-26 | 1988-06-28 | Fishgal Semyon I | Hollow article with zigzag projections |
| GB8828806D0 (en) * | 1988-12-09 | 1989-01-18 | Beecham Group Plc | Novel compounds |
| JP2967996B2 (ja) * | 1989-06-06 | 1999-10-25 | 協和醗酵工業株式会社 | Ｌ―トリプトファンの製造法 |
| US5120837A (en) * | 1989-09-20 | 1992-06-09 | The Nutrasweet Company | Dna encoding phe a feedback inhibition resistant enzyme analogues |
-
1992
- 1992-03-24 TW TW081102201A patent/TW313589B/zh active
- 1992-08-17 BR BR9206902A patent/BR9206902A/pt not_active Application Discontinuation
- 1992-08-17 AU AU24268/92A patent/AU668359B2/en not_active Expired
- 1992-08-17 HU HU9400796A patent/HU217795B/hu unknown
- 1992-08-17 ES ES92917826T patent/ES2084373T3/es not_active Expired - Lifetime
- 1992-08-17 US US08/244,491 patent/US5618716A/en not_active Expired - Lifetime
- 1992-08-17 JP JP5510540A patent/JP2584409B2/ja not_active Expired - Lifetime
- 1992-08-17 WO PCT/EP1992/001873 patent/WO1993012235A1/en not_active Ceased
- 1992-08-17 RU RU94030817/13A patent/RU2154671C1/ru active
- 1992-08-17 KR KR1019940701948A patent/KR0132258B1/ko not_active Expired - Lifetime
- 1992-08-17 DE DE69208894T patent/DE69208894T2/de not_active Expired - Lifetime
- 1992-08-17 CZ CZ941406A patent/CZ285915B6/cs not_active IP Right Cessation
- 1992-08-17 SK SK700-94A patent/SK279805B6/sk not_active IP Right Cessation
- 1992-08-17 EP EP92917826A patent/EP0620853B1/en not_active Expired - Lifetime
- 1992-08-17 CA CA002124214A patent/CA2124214C/en not_active Expired - Lifetime
- 1992-08-17 UA UA94005362A patent/UA39861C2/uk unknown
- 1992-08-25 ZA ZA926405A patent/ZA926405B/xx unknown
- 1992-10-10 CN CN92112014A patent/CN1065914C/zh not_active Expired - Lifetime
-
1994
- 1994-06-09 FI FI942711A patent/FI113665B/fi not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2346038C2 (ru) * | 2002-07-19 | 2009-02-10 | Ваккер Хеми Аг | Способ ферментативного получения аминокислот и производных аминокислот из семейства фосфоглицератов |
Also Published As
| Publication number | Publication date |
|---|---|
| HUT69802A (en) | 1995-09-28 |
| DE69208894T2 (de) | 1996-07-18 |
| US5618716A (en) | 1997-04-08 |
| AU2426892A (en) | 1993-07-19 |
| BR9206902A (pt) | 1995-11-21 |
| ZA926405B (en) | 1993-04-28 |
| CN1065914C (zh) | 2001-05-16 |
| ES2084373T3 (es) | 1996-05-01 |
| SK279805B6 (sk) | 1999-04-13 |
| AU668359B2 (en) | 1996-05-02 |
| WO1993012235A1 (en) | 1993-06-24 |
| FI113665B (fi) | 2004-05-31 |
| JPH06510911A (ja) | 1994-12-08 |
| EP0620853B1 (en) | 1996-03-06 |
| CA2124214A1 (en) | 1993-06-24 |
| SK70094A3 (en) | 1995-03-08 |
| TW313589B (cg-RX-API-DMAC10.html) | 1997-08-21 |
| CZ140694A3 (en) | 1995-01-18 |
| UA39861C2 (uk) | 2001-07-16 |
| CA2124214C (en) | 2002-04-02 |
| FI942711A0 (fi) | 1994-06-09 |
| FI942711L (fi) | 1994-06-09 |
| HU9400796D0 (en) | 1994-06-28 |
| DE69208894D1 (de) | 1996-04-11 |
| CZ285915B6 (cs) | 1999-11-17 |
| JP2584409B2 (ja) | 1997-02-26 |
| CN1073209A (zh) | 1993-06-16 |
| EP0620853A1 (en) | 1994-10-26 |
| KR0132258B1 (ko) | 1998-04-11 |
| HU217795B (hu) | 2000-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2154671C1 (ru) | Днк-фрагмент, кодирующий 3-фосфоглицератдегидрогеназу (фгд), фгд, способ получения серина | |
| JP3331472B2 (ja) | 発酵法によるｌ−スレオニンの製造法 | |
| JPH02458A (ja) | 発酵法によるｌ―イソロイシンの製造法 | |
| US7851610B2 (en) | Transporter protein | |
| KR19990067120A (ko) | O-아세틸세린, l-시스테인 및 l-시스테인 유도 생성물의제조방법 | |
| JP4695855B2 (ja) | Ｌ−セリンによる阻害の減少を示す３−ホスホグリセレートデヒドロゲナーゼの変異体およびそれをコードする遺伝子、ならびにその使用 | |
| KR101991206B1 (ko) | cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법 | |
| KR101996767B1 (ko) | cAMP 수용 단백질 변이체 및 이를 이용한 L-아미노산 제조방법 | |
| US5856148A (en) | Materials and methods for biosynthesis of serine and serine-related products | |
| CN116802283A (zh) | 组氨酸导致的反馈抑制得到减少的atp-prt变体及表达该变体的组氨酸生产菌株 | |
| CN116745412A (zh) | 组氨酸导致的反馈抑制得到减少的atp-prt变体及表达该变体的组氨酸生产菌株 | |
| CN116783290A (zh) | 组氨酸导致的反馈抑制得到减少的atp-prt变体及表达该变体的组氨酸生产菌株 | |
| JP5813512B2 (ja) | リボフラビンの生産方法 | |
| DK2430152T3 (en) | A microorganism with increased L-lysine productivity and method for producing L-lysine using the same | |
| KR20150121789A (ko) | 2,3―부탄디올의 생성능이 증강된 재조합 미생물 및 이를 이용한 2,3―부탄디올의 생산 방법 | |
| JPH11346776A (ja) | ブレビバクテリウム・ラクトファーメンタムのシトクロムｂｄ型キノールオキシダーゼ遺伝子 | |
| JP4455601B2 (ja) | コリネバクテリウム由来の新規ｌ−スレオニンインポーター及びｌ−スレオニン産生株の作製方法 | |
| KR101551533B1 (ko) | 2,3-부탄디올의 생성능이 증강된 재조합 미생물 및 이를 이용한 2,3-부탄디올의 생산 방법 | |
| WO2024013212A1 (en) | Microbial cell factories producing thiamine | |
| KR101755349B1 (ko) | L-쓰레오닌 생산능을 가지는 미생물 및 그를 이용하여 l-쓰레오닌을 생산하는 방법 | |
| JP3518501B2 (ja) | 酸化還元酵素遺伝子、同遺伝子のクローニングおよび同酵素の製造方法 | |
| JP3496640B2 (ja) | 酸化還元酵素、同酵素をコードする遺伝子、同酵素遺伝子含有形質転換体および同酵素の製造方法 | |
| JPS63269986A (ja) | 遺伝子調節単位および、クローニング・発現系 | |
| WO2003068978A2 (fr) | Combinaisons de vecteurs et leurs hotes pour propager et exprimer des genes recombinants sans recourir a des antibiotiques |